Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III double-blind randomized trial of asenapine maleate sublingual tablets in acute schizophrenia
CTR20222759Phase 3Completed
- Sponsor
- Harbin Sanlian Pharmaceutical
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of asenapine in schizophrenia, sponsored by Harbin Sanlian Pharmaceutical. Started Oct 2022; status: completed.
02
Drugs
asenapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on CTR20222759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222759.